Toad Venom Turbocharges Depression Arms Race

The U.S. Food and Drug Administration (FDA) just fast-tracked a drug made from toad venom — and a race worth billions of dollars is now underway to turn it into a mainstream mental health treatment.

Story Snapshot

The FDA granted Breakthrough Therapy Designation to BPL-003, an intranasal form of 5-MeO-DMT, for treatment-resistant depression in late 2025.
Multiple biotech companies are now competing to be first to market with 5-MeO-DMT, a psychedelic far more potent than psilocybin.
Early clinical trials show rapid antidepressant effects — sometimes within 24 hours — but large-scale Phase 3 data is still thin.
The FDA’s 2024 rejection of MDMA therapy for PTSD serves as a stark warning that a fast-track designation is not a guarantee of approval.

The Drug That Comes From a Toad

5-MeO-DMT is a naturally occurring compound found in the venom of the Sonoran Desert toad. It also exists in certain plants. Users report an intense, ego-dissolving experience that lasts only 15 to 30 minutes. That short duration is actually a selling point for drug developers — shorter sessions mean lower clinic costs and faster patient turnover. Researchers have been studying it quietly for years, but 2025 marked the moment it stepped into the commercial spotlight.

Treatment-resistant depression is the target. Up to 30% of the roughly 280 million people worldwide who suffer from depression do not respond to standard antidepressants. That is a massive unmet need, and it explains why pharma companies are moving fast. Veterans dealing with post-traumatic stress disorder are also a key focus, given the well-documented failure of conventional treatments for that population.

What the FDA’s Breakthrough Designation Actually Means

The FDA granted its Breakthrough Therapy Designation to BPL-003, a drug developed by Beckley Psytech and Atai Life Sciences, in October 2025. This designation is designed to speed up development and review of drugs that show early promise for serious conditions. It does not mean the drug is approved. It means the FDA will work more closely with the company during trials. Think of it as a green light to run faster — not a finish line crossed.

Separately, the FDA lifted a two-year clinical hold on GH Research’s inhalable version of 5-MeO-DMT in early 2026, clearing the way for that Dublin-based company to resume its own trials. At least one other firm, Transcend Therapeutics, has received expedited review status for a related program. The competition is real, and it is accelerating.

Early Trial Results Are Promising but Limited

In a Phase 2b study, patients who received the highest dose of BPL-003 — 12 mg — saw their depression scores drop by an average of 11.1 points, compared to a 5.8 point drop in the placebo group. A separate Phase 1/2 trial of GH Research’s inhalable version found that 87.5% of patients in the highest-dose group met remission criteria by day seven. Those are striking numbers. But both studies involved small groups of patients, and neither has been replicated at the scale the FDA requires for full approval.

Early safety data is encouraging. In a 44-participant trial of intranasal BPL-003, no serious side effects were recorded and no patients dropped out. The most common complaints were nasal discomfort, nausea, and brief headaches. Short-term tolerability looks solid. Long-term data, however, remains scarce.

The MDMA Warning Nobody Should Ignore

In August 2024, the FDA rejected MDMA-assisted therapy for PTSD — the first time the agency had ever turned down a psychedelic treatment. MDMA had held a Breakthrough Therapy Designation since 2017. It had years of promising Phase 2 data. It still failed. The FDA cited insufficient evidence and raised concerns about trial design. That decision should serve as a cold dose of reality for every investor and company now betting big on 5-MeO-DMT.

The Race to Commercialize the World’s Most Powerful Psychedelic – The Wall Street Journal https://t.co/D40EPWEgje

— PillowTalk W/ LauLei (@PillowTalkLau) July 19, 2026

The pattern here is familiar. A psychedelic compound gets a Breakthrough Designation, investor money floods in, and the hard science scrambles to keep up. Psilocybin got its first Breakthrough Designation in 2018 and is only now entering Phase 3 trials. 5-MeO-DMT is earlier in that process. The FDA has also finalized formal guidance for psychedelic clinical trials, setting clearer rules for how these studies must be designed and conducted. That is a good sign for the field’s long-term credibility — but it also raises the bar for approval. Companies that cut corners on trial design will pay the price, just as the MDMA developers did. The science needs to lead the money, not chase it.